Literature DB >> 30421447

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Minh P Lê1,2, Marie-Laure Chaix3, François Raffi4, Sylvie Chevret5, Sébastien Gallien6, Christine Katlama7, Pierre Delobel8, Yazdan Yazdanpanah1,9, Juliette Saillard10, Jean-Michel Molina11, Gilles Peytavin1,2.   

Abstract

Entities:  

Keywords:  darunavir; dose reduction; seminal and blood plasma; unbound total

Mesh：

Substances：

Year:  2018        PMID： 30421447      PMCID： PMC6303241          DOI： 10.1111/bcp.13796

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

1.  HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen.

Authors:  A Lafeuillade; C Solas; S Chadapaud; G Hittinger; C Poggi; B Lacarelle
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-01       Impact factor: 3.731

2.  Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Authors:  Alain Lafeuillade; Caroline Solas; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

3.  Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Authors:  Minh P Lê; Marie-Laure Chaix; François Raffi; Sylvie Chevret; Sébastien Gallien; Christine Katlama; Pierre Delobel; Yazdan Yazdanpanah; Juliette Saillard; Jean-Michel Molina; Gilles Peytavin
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

4.  Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Authors:  Elodie Valade; Jean-Marc Tréluyer; Silvia M Illamola; Naïm Bouazza; Frantz Foissac; Maïlys De Sousa Mendes; Gabrielle Lui; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Déborah Hirt; Saïk Urien; Jade Ghosn
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

5.  HIV-1 Populations in Semen Arise through Multiple Mechanisms.

Authors:  Jeffrey A Anderson; Li-Hua Ping; Oliver Dibben; Cassandra B Jabara; Leslie Arney; Laura Kincer; Yuyang Tang; Marcia Hobbs; Irving Hoffman; Peter Kazembe; Corbin D Jones; Persephone Borrow; Susan Fiscus; Myron S Cohen; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

6.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Authors:  Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

7.  Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.

Authors:  Elodie Valade; Naïm Bouazza; Gabrielle Lui; Silvia M Illamola; Sihem Benaboud; Jean-Marc Treluyer; Aurélie Cobat; Frantz Foissac; Maïlys De Sousa Mendes; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Saïk Urien; Jade Ghosn; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).

Authors:  Jean-Michel Molina; Sebastien Gallien; Marie-Laure Chaix; El Mountacer El Abbassi; Isabelle Madelaine; Christine Katlama; Nadia Valin; Pierre Delobel; Kristell Desseaux; Gilles Peytavin; Juliette Saillard; François Raffi; Sylvie Chevret
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

9.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.

Authors:  Minh P Lê; Linda Belarbi; Marie-Laure Chaix; Emmanuel Dulioust; Nadia Mahjoub; Dominique Salmon; Jean-Paul Viard; Claudine Duvivier; Gilles Peytavin; Odile Launay; Jade Ghosn
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790
View more
  1 in total

1.  Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Authors:  Minh P Lê; Marie-Laure Chaix; François Raffi; Sylvie Chevret; Sébastien Gallien; Christine Katlama; Pierre Delobel; Yazdan Yazdanpanah; Juliette Saillard; Jean-Michel Molina; Gilles Peytavin
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.